Subclinical hypothyroidism (TSH ≥7 mIU/L) and isolated low T3 levels are markers of poor prognosis in heart failure, highlighting the need for future clinical trials on thyroid hormone supplementation.
In patients with preexisting heart failure, subclinical hypothyroidism with TSH ≥7 mIU/L and isolated low T3 levels are associated with poor prognosis. Clinical trials are needed to explore therapeutic effects of T4 and T3 administration in heart failure.
Kannan et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: